Copper/Cholesterol Interaction in Alzheimer's Disease

Principal Investigator
Ashley Bush, MD, PhD
Mental Health Research Institute
Parkville, Victoria, Australia
About the Research Project
Program
Award Type
Standard
Award Amount
$300,000
Active Dates
April 01, 2005 - March 31, 2007
Grant ID
A2005091
Summary
In Alzheimer’s disease a normal protein called beta-amyloid (Aβ) has been found to accumulate abnormally in the brain. AD has also been associated with abnormalities in cholesterol metabolism. Both links, however, are complex and the results of their specific effects have not yet been pin-pointed. Dr. Bush’s team has discovered Aβ to be a copper binding protein. Copper (like cholesterol) is a normally abundant part of brain chemistry, but in AD Aβ abnormally utilizes copper’s chemical energy to convert cholesterol into hydrogen peroxide. This is a damaging reaction that may be the cause of the toxicity of Aβ. Through a five part research analysis, Dr. Bush’s studies will help illuminate the complex biochemistry of Aβ in its reactions with copper and cholesterol in the brain.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015

Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Alzheimer's Disease Research
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026

Principal Investigator
Olav Andersen, PhD